已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Trial of Deferiprone in Parkinson’s Disease

脱铁酮 医学 帕金森病 内科学 疾病 地中海贫血
作者
David Devos,Julien Labreuche,Olivier Rascol,Jean‐Christophe Corvol,Alain Duhamel,Pauline Guyon Delannoy,Werner H Poewe,Yaroslau Compta,Nicola Pavese,Evžen Růžička,Petr Dušek,Bart Post,Bastiaan R. Bloem,Daniela Berg,Walter Maetzler,Markus Otto,Marie‐Odile Habert,Stéphane Lehéricy,Joaquim José Ferreira,Richard C. Dodel
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:387 (22): 2045-2055 被引量:293
标识
DOI:10.1056/nejmoa2209254
摘要

BACKGROUND: Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its effects on disease progression are unclear. METHODS: We conducted a multicenter, phase 2, randomized, double-blind trial involving participants with newly diagnosed Parkinson's disease who had never received levodopa. Participants were assigned (in a 1:1 ratio) to receive oral deferiprone at a dose of 15 mg per kilogram of body weight twice daily or matched placebo for 36 weeks. Dopaminergic therapy was withheld unless deemed necessary for symptom control. The primary outcome was the change in the total score on the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS; range, 0 to 260, with higher scores indicating more severe impairment) at 36 weeks. Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content measured with the use of magnetic resonance imaging was also an exploratory outcome. RESULTS: A total of 372 participants were enrolled; 186 were assigned to receive deferiprone and 186 to receive placebo. Progression of symptoms led to the initiation of dopaminergic therapy in 22.0% of the participants in the deferiprone group and 2.7% of those in the placebo group. The mean MDS-UPDRS total score at baseline was 34.3 in the deferiprone group and 33.2 in the placebo group and increased (worsened) by 15.6 points and 6.3 points, respectively (difference, 9.3 points; 95% confidence interval, 6.3 to 12.2; P<0.001). Nigrostriatal iron content decreased more in the deferiprone group than in the placebo group. The main serious adverse events with deferiprone were agranulocytosis in 2 participants and neutropenia in 3 participants. CONCLUSIONS: In participants with early Parkinson's disease who had never received levodopa and in whom treatment with dopaminergic medications was not planned, deferiprone was associated with worse scores in measures of parkinsonism than those with placebo over a period of 36 weeks. (Funded by the European Union Horizon 2020 program; FAIRPARK-II ClinicalTrials.gov number, NCT02655315.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
在水一方的应助被人间理想采纳,获得10
1秒前
1秒前
脑洞疼的应助被长情的雨采纳,获得10
1秒前
1秒前
weather_clear完成签到 ,获得积分10
2秒前
2秒前
3秒前
布洛芬发布了新的文献求助10
4秒前
汉堡包的应助被耳东采纳,获得10
6秒前
邱c发布了新的文献求助10
6秒前
2026221709发布了新的文献求助30
6秒前
徐豆芽完成签到,获得积分20
6秒前
huanfeng完成签到,获得积分10
7秒前
CipherSage的应助被monster采纳,获得10
8秒前
Fascinate完成签到 ,获得积分10
9秒前
Rr发布了新的文献求助10
9秒前
10秒前
12秒前
12秒前
Luvv完成签到,获得积分10
14秒前
阳光发布了新的文献求助10
15秒前
16秒前
人间理想发布了新的文献求助10
16秒前
机智的兔子完成签到,获得积分10
17秒前
17秒前
耳东发布了新的文献求助10
18秒前
19秒前
无极微光的应助被Jonathan采纳,获得20
19秒前
啦啦啦发布了新的文献求助10
19秒前
Ava的应助被JiaYouguo采纳,获得10
19秒前
菜菜完成签到,获得积分10
22秒前
hoichai发布了新的文献求助10
22秒前
22秒前
喜悦寒凝发布了新的文献求助10
24秒前
24秒前
传奇3的应助被monster采纳,获得10
25秒前
桐桐的应助被nine采纳,获得10
26秒前
小二郎的应助被照亮世界的ay采纳,获得30
26秒前
zzzz完成签到,获得积分20
28秒前
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184536
求助须知:如何正确求助?哪些是违规求助? 9573526
关于积分的说明 21832132
捐赠科研通 7781791
什么是DOI,文献DOI怎么找? 3434376
关于科研通互助平台的介绍 2558490
邀请新用户注册赠送积分活动 2480989